Cipla Limited has fixed June 5, 2026, as the record date for the payment of its final dividend for the financial year ended March 31, 2026. The Board of Directors had previously recommended a final dividend of INR 13 per equity share of face value INR 2 each, subject to the approval of shareholders at the ensuing Annual General Meeting (AGM). The company announced that the 90th AGM will be held through video conferencing on Thursday, June 25, 2026, at 2:00 PM IST.

The audited financial results for the financial year ended March 31, 2026, were approved by the Board on May 13, 2026. The company reported its highest-ever yearly consolidated revenue of INR 28,163 Cr for FY26. However, net profit declined sharply to INR 3,879.23 Cr from INR 5,272.52 Cr in the previous year. EBITDA for the year stood at INR 5,925 Cr, with a margin of 21.0%, which fell short of the company's full-year guidance of 24%.

On a standalone basis, total revenue from operations for FY26 was INR 18,979.95 Cr, compared to INR 19,044.85 Cr in the prior year. Net profit after tax was INR 3,515.18 Cr, against INR 5,157.65 Cr in FY25. Basic earnings per share (EPS) for FY26 stood at ₹48.03 on a consolidated basis and ₹43.52 on a standalone basis.

The One India business grew 9% YoY to reach INR 12,680 Cr, while North America delivered an annual revenue of $780 Mn, a decline of 13% YoY. The company maintained a strong net cash position of INR 10,526 Cr as of March 31, 2026. Cipla has outlined a robust pipeline strategy for its North America division, with 5 respiratory assets filed and 8 assets in the peptides and complex generics space filed, with launches anticipated in FY27–FY28.

Cipla has attracted a divergence of analyst opinions, with JPMorgan upgrading the stock, Citi reaffirming its bullish stance with a higher target, and HSBC maintaining a cautious hold. Adding further context, management's concall update has outlined key financial and operational targets, including a $1 billion North America run rate by the end of FY27. The varying perspectives reflect differing assessments of the company's US business trajectory, margin sustainability, and pipeline execution risks.

Management Concall Highlights

Cipla's management has outlined an ambitious roadmap for its North America business, targeting a $1 billion run rate by the end of FY27, driven by new product launches with a significant ramp-up anticipated in the second half of the year. Notably, this guidance excludes any contribution from Lanreotide. On the margin front, gross margins are anticipated to carry a positive bias, supported by the higher margin profile of in-house respiratory products, a shift towards chronic therapies in India, and ongoing cost control initiatives — despite potential temporary impacts from geopolitical situations. For the One India business, management has expressed confidence in delivering strong double-digit growth and outperforming the market in FY27–28, building on consistent trends observed in recent quarters. EBITDA margins for FY27 are projected in the range of 18.5% to 20%, with sequential improvement expected primarily in the second half of the year, and this guidance also excludes any contribution from Lanreotide.

JPMorgan Upgrades to Overweight

JPMorgan has upgraded Cipla to Overweight, assigning a target price of ₹1550. The upgrade is underpinned by improved earnings visibility stemming from a robust US launch pipeline. Key upcoming launches cited include gVentolin, gAdvair, gSymbicort, and peptides. The brokerage also highlighted management's FY27 US revenue run-rate guidance of $1 billion as a significant positive catalyst. Additionally, JPMorgan noted that Cipla's valuations have turned attractive following a recent correction, with the stock currently trading at a discount to peers such as Dr. Reddy's and Lupin.

Citi Maintains Buy with Raised Target

Citi has maintained its Buy rating on Cipla while raising its target price to ₹1700. The brokerage cited strong Q4 trends, led by ~15% India growth, as well as resilient US sales performance despite the phase-out of gRevlimid and Lanreotide. Gross margin expansion was flagged as another positive development. Citi pointed to a positive FY27 outlook anchored by the $1 billion US sales run-rate target and strong pipeline visibility. Management has expressed confidence in sustaining 18.5–20% EBITDA margins in FY27, with potential for FY28 EBITDA margins to exceed 21% if pipeline execution stays on track, even amid input cost pressures.

HSBC Holds with Cautious Outlook

HSBC has maintained its Hold rating on Cipla with a target price of ₹1340. The brokerage flagged a Q4FY26 miss and noted that FY27 EBITDA margin guidance of 18.5–20% factors in no resolution in Lanreotide supplies. HSBC emphasized that execution of upcoming launches remains crucial for achieving the targeted $1 billion annualized US sales run-rate, with further progress in US sales seen as key to sustaining growth momentum.

Analyst Ratings at a Glance

The following table summarizes the current analyst ratings and key metrics for Cipla:

Key Themes Across Analyst Views

Despite differing ratings, several common themes emerge across the three brokerages and management's concall update:

• US Revenue Target: All three analysts and management reference the FY27 US revenue run-rate guidance of $1 billion as a central milestone, with the guidance explicitly excluding Lanreotide contributions.
• Pipeline Execution: The successful launch of products including gVentolin, gAdvair, gSymbicort, and peptides is consistently highlighted as critical to achieving growth targets, with a significant ramp-up expected in H2.
• Margin Sustainability: EBITDA margin guidance of 18.5–20% for FY27 is a focal point, with input cost pressures and Lanreotide supply issues cited as potential headwinds. Gross margins are expected to benefit from in-house respiratory products and a shift towards chronic therapies.
• India Business Strength: Management's confidence in delivering strong double-digit growth for the One India business in FY27–28 is corroborated by Citi's observation of ~15% India growth trends.
• Lanreotide Phase-Out: The wind-down of Lanreotide contributions is acknowledged across multiple analyst notes and management guidance as a factor influencing near-term US sales performance.